Company profile: BridGene Biosciences
1.1 - Company Overview
Company description
- Provider of chemoproteomics-driven small-molecule discovery and development via the IMTAC platform that screens small molecules against all proteins in live cells; a covalent small-molecule library targeting diverse amino acids; live-cell screening and quantitative mass spec analysis services; and drug development for undruggable targets, particularly in oncology, with partnerships such as Takeda.
Products and services
- Covalent Small Molecule Library: Custom-engineered library of covalent small molecules designed to target different amino acids, enabling discovery of ligands for more proteins across the proteome
- Custom-engineered
- Drug Development: Engineers small-molecule therapeutics targeting previously undruggable targets, with particular emphasis on oncology indications, advancing discovery into development
- Oncology-focused
- IMTAC™ Platform: Proteome-wide, live-cell chemoproteomics system that screens small molecules against all proteins to discover drug candidates for high-value and hard-to-drug targets
- Proteome-wide
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BridGene Biosciences
Sarissa Biomedical
HQ: United Kingdom
Website
- Description: Provider of minimally invasive microelectrode electrochemical biosensors that detect purines and other neurochemicals, such as serotonin and dopamine, in blood to aid diagnosis and monitoring of neurological disorders. Solutions offer exquisite sensitivity, broad linear range, rapid measurements, and high accuracy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sarissa Biomedical company profile →
Biosensia
HQ: Ireland
Website
- Description: Provider of point-of-care in-vitro diagnostics platforms. Offers RapiPlex, a rapid, multiplexing POC IVD platform available for licensing, enabling access to a broad range of diagnostic applications and used with a variety of common biological sample types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosensia company profile →
Biotix
HQ: United States
Website
- Description: Provider of laboratory consumables and liquid handling solutions, including pipette tips (xTIP4, uTIP, aTIP), the Ergonomix manual pipetting system with light ejection, assay and deep well plates made from medical-grade virgin polypropylene, reagent reservoirs certified free of DNase/RNase/endotoxins, OEM custom consumables design and manufacturing, and Defender face shields for splash protection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotix company profile →
SeqLL
HQ: United States
Website
- Description: Provider of molecule sequencing technology for research and healthcare communities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeqLL company profile →
ViaCord
HQ: United States
Website
- Description: Provider of women's health biotechnology services, including ViaCord for preserving newborn umbilical cord blood, cord tissue banking, and ViaCyte for cryopreservation of unfertilized eggs, plus newborn genomic offerings such as DNA preservation, celiac and lactose risk testing, a panel analyzing over 270 genes, and whole genome sequencing of 22,000 genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViaCord company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BridGene Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BridGene Biosciences
2.2 - Growth funds investing in similar companies to BridGene Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BridGene Biosciences
4.2 - Public trading comparable groups for BridGene Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →